SG11202105137RA - Application of chidamide in combination with r-chop, and drug combination - Google Patents
Application of chidamide in combination with r-chop, and drug combinationInfo
- Publication number
- SG11202105137RA SG11202105137RA SG11202105137RA SG11202105137RA SG11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA
- Authority
- SG
- Singapore
- Prior art keywords
- combination
- chidamide
- chop
- application
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811394614 | 2018-11-20 | ||
PCT/CN2019/119170 WO2020103788A1 (fr) | 2018-11-20 | 2019-11-18 | Application du chidamide associé à r-chop et combinaison de médicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105137RA true SG11202105137RA (en) | 2021-06-29 |
Family
ID=70741744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105137RA SG11202105137RA (en) | 2018-11-20 | 2019-11-18 | Application of chidamide in combination with r-chop, and drug combination |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220016147A1 (fr) |
EP (1) | EP3884943A4 (fr) |
JP (1) | JP7489397B2 (fr) |
KR (1) | KR20210104059A (fr) |
CN (2) | CN117797149A (fr) |
AU (1) | AU2019385373A1 (fr) |
BR (1) | BR112021009627A2 (fr) |
CA (1) | CA3120207A1 (fr) |
PH (1) | PH12021551138A1 (fr) |
SG (1) | SG11202105137RA (fr) |
TW (1) | TWI768263B (fr) |
WO (1) | WO2020103788A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118161618A (zh) * | 2020-06-18 | 2024-06-11 | 苏州亚盛药业有限公司 | 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途 |
CN112274509B (zh) * | 2020-12-02 | 2022-04-26 | 四川大学华西医院 | 西达本胺联合bcl2抑制剂在双表达型b细胞淋巴瘤中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100924737B1 (ko) * | 2003-08-26 | 2009-11-04 | 슬로안-케테링인스티튜트퍼캔서리서치 | Hdac 억제제를 이용한 암의 치료 방법 |
CN101470112A (zh) * | 2007-12-28 | 2009-07-01 | 上海交通大学医学院附属瑞金医院 | 弥漫性大b细胞淋巴瘤治疗指导和预后判断的分子标志物 |
TWI808055B (zh) * | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
CA3031365A1 (fr) | 2016-07-20 | 2018-01-25 | The Trustees Of Columbia University In The City Of New York | Activateurs d'histone acetyltransferase et compositions et utilisations associees |
CN107157978B (zh) * | 2017-05-24 | 2021-06-18 | 中国药科大学 | 治疗ebv+dlbcl和dlbcl的药物及组合物 |
CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
-
2019
- 2019-03-25 CN CN202311474046.2A patent/CN117797149A/zh active Pending
- 2019-03-25 CN CN201910228406.8A patent/CN111195249B/zh active Active
- 2019-11-18 SG SG11202105137RA patent/SG11202105137RA/en unknown
- 2019-11-18 US US17/295,494 patent/US20220016147A1/en active Pending
- 2019-11-18 JP JP2021551329A patent/JP7489397B2/ja active Active
- 2019-11-18 TW TW108141826A patent/TWI768263B/zh active
- 2019-11-18 WO PCT/CN2019/119170 patent/WO2020103788A1/fr active Application Filing
- 2019-11-18 CA CA3120207A patent/CA3120207A1/fr active Pending
- 2019-11-18 EP EP19887480.2A patent/EP3884943A4/fr active Pending
- 2019-11-18 KR KR1020217018968A patent/KR20210104059A/ko active Search and Examination
- 2019-11-18 AU AU2019385373A patent/AU2019385373A1/en active Pending
- 2019-11-18 BR BR112021009627-2A patent/BR112021009627A2/pt unknown
-
2021
- 2021-05-19 PH PH12021551138A patent/PH12021551138A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022511126A (ja) | 2022-01-28 |
CN117797149A (zh) | 2024-04-02 |
US20220016147A1 (en) | 2022-01-20 |
WO2020103788A1 (fr) | 2020-05-28 |
TWI768263B (zh) | 2022-06-21 |
CA3120207A1 (fr) | 2020-05-28 |
CN111195249A (zh) | 2020-05-26 |
PH12021551138A1 (en) | 2022-02-21 |
EP3884943A4 (fr) | 2022-07-06 |
TW202033194A (zh) | 2020-09-16 |
JP7489397B2 (ja) | 2024-05-23 |
CN111195249B (zh) | 2023-11-28 |
EP3884943A1 (fr) | 2021-09-29 |
AU2019385373A1 (en) | 2021-06-24 |
KR20210104059A (ko) | 2021-08-24 |
BR112021009627A2 (pt) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284835A (en) | Pharmaceutical combination containing TNO155 and ribociclib | |
IL279015A (en) | Anti-interleukin-17A antibody, its pharmaceutical preparation and its use | |
SG11202003320SA (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
SG11202105173VA (en) | Modified cell expressing therapeutic agent and uses thereof | |
SG11202001647UA (en) | Conjugate of vegf-grab protein and drug, and use thereof | |
GB201604213D0 (en) | Drug combination and its use in therapy | |
PT3615035T (pt) | Utilização de 20-hidroxiecdisona e os seus derivados no tratamento de miopatias | |
IL273339A (en) | Griseofulbin compound and its medical use | |
DK3275453T3 (da) | Farmaceutisk sammensætning med silibinin og ve | |
GB201820659D0 (en) | Novel compostions and their use in therapy | |
IL282527A (en) | 5-Azaindazole history and their use | |
PL3658122T3 (pl) | Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan | |
DK3334760T3 (da) | Antistofcysteiner med kappe og uden kappe, og deres anvendelse i antistof-lægemiddel-konjugering | |
EP3630124A4 (fr) | Composition synthétique comprenant des oligosaccharides et son utilisation dans un traitement médical | |
SG11202105137RA (en) | Application of chidamide in combination with r-chop, and drug combination | |
GB201709840D0 (en) | Methods and medical uses | |
SG11202101435XA (en) | ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
SG11202004529XA (en) | Transformed human cell and use thereof | |
IL282526A (en) | 5-Azaindazole history and their use | |
SG11201906132UA (en) | Insoluble complex or solvate thereof, pharmaceutical composition and use thereof | |
EP3696178A4 (fr) | Composé hétérocyclique et son application en médecine | |
EP3615064A4 (fr) | Compositions cellulaires enrichies et utilisation thérapeutique | |
GB201519644D0 (en) | Therapy and pharmaceutical composition | |
PL3212280T3 (pl) | Dopasowanie szumu usznego u pacjentów z implantem ślimakowym (CI) i implantem słuchowym pnia mózgu (ABI) | |
SG11202103806VA (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament |